Avidea’s immunotherapies are enabled by innovations
in polymer-based drug-delivery.
The SNAP Platform is based on amphiphilic polymer-drug conjugates that are chemically programmed to self-assemble into nanoparticles.
Enhanced biological activity
Avidea’s SNAP Platform (Self-assembling Nanoparticles based on Amphiphilic Polymers) packages drug molecules into nanoparticles of uniform size that are designed to target specific tissues and cell populations. Packaging drug molecules into nanoparticles focuses drug molecules where activity is needed and prevents off-target side effects.
Through precise control of pharmacokinetics, SNAP enables improved safety and efficacy as compared with unpackaged drugs. When used as a cancer vaccine in preclinical models, Avidea’s SNAP Platform packages peptide antigens and immunostimulants into nanoparticles that target antigen-presenting cells, leading to high magnitude tumor-specific T cell responses.
Chemically-defined particles with precise drug loading
Conventional particle drug delivery systems rely on an empirical formulation process for loading drug molecules, often resulting in heterogeneous particle sizes, low drug loading, and costly loss of unincorporated drug.
Avidea’s amphiphilic polymer-drug conjugates are designed to self-assemble into nanoparticles of uniform size with precise drug loading (no variability) and minimal drug molecule loss during manufacturing.
Sterile filtration without material loss
During manufacturing, injectable drug products must be passed through a sterile filter. Conventional particle drug delivery systems often clog sterile filters, yielding low and/or variable particle concentrations following filtration.
Avidea’s amphiphilic polymer-drug conjugates – as soluble single molecules – readily pass through sterile filters without material loss. Nanoparticle assembly occurs spontaneously after the filtration process, thereby overcoming a major manufacturing challenge.